1横田慎一 熊毅雄治 内海光朝.A Pharmacokinetic Study of MCI—186,a novel drug for cerebrovascular disease in elderly and young healthy subjects[J].临床药理,1997,28(3):693-702.
2Mizuno A,Umemura K,Nakashima M.Inhibitory effect MCI-186,a free radical scavenger,on cerebral ischemia following rat middle cerebral artery occlusion[J].Gen Pharmacol,1998,30(4)∶575-578.
3Kawai H,Nakai H,Misao S,et al.Effects of a novel free radical scavenger,MCI-186,on ischemic brain damage in the rat distal middle cerebral artery occlusion model[J].J Pharmacol Exp Ther,1997,281(2)∶921-927.
5Yamamoto T,Yuki S,Watanabe T,et al.Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia[J].Brain Res,1997,762(12)∶240-242.
6Watanabe T,Egawa M.Effects of an antistroke agent MCI-186 on cerebral arachidonate cascades[J].J Pharmacol Exp Ther,1994,271(3)∶1624-1629.
7Watanabe T,Morita I,Nishi H,et al.Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro[J].Prostaglandins Leukotrienes Essent Fatty Acids,1998,33(1)∶81-87.
8Mitsumori K,Sakuragi M,Kitami K,et al.The effect MCI-186 on regional cerebral blood flow in patients with acute cerebral infarction-A sequential SPECT study[J].Ther Res,1998,19(4)∶1333-1345.
9山本美奈子 高松康雄.Pharmacokinetic studies of 3—methyl—1—phenyl—2—pyrazolin—5—one（MCI—186）：protein binding and distribution to red blood cell[J].药理と治疗,1997,25(17):1755-1763.
